1 Title: SARS-CoV-2 variants of concern Alpha and Delta show increased viral load in

- 2 saliva
- 3
- 4 **Authors:** Kylie L. King¹, Stevin Wilson², Justin M. Napolitano¹, Keegan J. Sell¹, Lior Rennert³,
- 5 Christopher L. Parkinson^{2,4}, Delphine Dean^{1,5}.
- 6
- 7

8 Affiliations:

- ¹Center for Innovative Medical Devices and Sensors (REDDI Lab), Clemson University,
- 10 Clemson, South Carolina, United States of America.
- ²Clemson University Genomics and Bioinformatics Facility, Clemson, South Carolina, United
 States of America.
- ³Department of Public Health Sciences, Clemson University, Clemson, South Carolina, United
 States of America.
- ⁴Department of Biological Sciences and Department of Forestry and Environmental
- 16 Conservation, Clemson University, Clemson, South Carolina, United State of America
- ⁵Department of Bioengineering, Clemson University, Clemson, South Carolina, United States of
- 18 America.
- 19

- 20 Short Title: Viral Load of SARS-COV-2 Variants
- 22 **Corresponding Author:** Delphine Dean, 864-656-2611, finou@clemson.edu
- 23
- 24
- 25

26 Abstract:

27 Background

28 Higher viral loads in SARS-CoV-2 infections may be linked to more rapid spread of emerging

- 29 Variants of Concern. Rapid detection and isolation of cases with highest viral loads, even in pre-
- 30 or asymptomatic individuals, is essential for the mitigation of community outbreaks.

31 Methods and Findings

32 In this study, we analyze Ct values from 1297 SARS-CoV-2 positive patient saliva samples

33 collected at the Clemson University testing lab in Upstate South Carolina. Samples were

34 identified as positive using RT-qPCR, and clade information was determined via whole genome

35 sequencing at nearby commercial labs. We also obtained patient-reported information on

36 symptoms and exposures at the time of testing. The lowest Ct values were observed among

37 those infected with Delta (median: 22.61, IQR: 16.72-28.51), followed by Alpha (23.93, 18.36-

38 28.49), Gamma (24.74, 18.84-30.64), and the more historic clade 20G (25.21, 20.50-29.916).

39 There was a statistically significant difference in Ct value between Delta and all other clades (all

40 p.adj<0.01), as well as between Alpha and 20G (p.adj<0.05). Additionally, pre- or asymptomatic

41 patients (n=1093) showed the same statistical differences between Delta and all other clades

42 (all p.adj<0.01); however, symptomatic patients (n=167) did not show any significant differences

43 between clades. Our weekly testing strategy ensures that cases are caught earlier in the

44 infection cycle, often before symptoms are present, reducing this sample size in our population.

45 Conclusions

COVID-19 variants Alpha and Delta have substantially higher viral loads in saliva compared to
more historic clades. This trend is especially observed in individuals who are pre- or
asymptomatic, which provides evidence to the high transmissibility and rapid spread of
emerging variants. Understanding the viral load of variants spreading within a community can
inform public policy and clinical decision making.

52

53 Introduction:

The United States confirmed its first positive SARS-CoV-2 case on January 21, 2020 [1]. As of December 1, 2021, there have been over 265 million cases globally and 48 million in the United States alone. Most recently, clade 21A, classified as the Delta variant, spread rapidly across the globe. On May 29, 2021, the CDC reported that 7.3% of new cases in the U.S.A. were identified as Delta, and 65.4% of cases were clade 20I (Alpha). By August 28, 99.1% of reported cases were Delta [1]. This rapid shift may be attributed to key mutations that increase transmissibility due in part to a higher viral load.

61 In early 2021, the Alpha variant spread rapidly due to the N501Y mutation in the S 62 protein which enhances its affinity for ACE2. The Delta variant lacks this mutation but carries 63 several mutations within the S protein; specifically, L452R, T478K, and P681R, which confer 64 resistance to monoclonal antibody treatments [2]. The L452R and T478K mutations may also 65 increase transmissibility of the virus by stabilizing the ACE2-RBD complex [2]. Another mutation 66 within the N protein, R203M, increases viral mRNA delivery and expression and facilitates the 67 Delta variant to produce >50-fold more viral particles [3]. These mutations may improve host cell 68 binding affinity, as well as increase viral production, and may contribute to the rapid global 69 spread of this variant.

70 Most studies of SARS-CoV-2 viral loads used the nasopharyngeal (NP) swab sample 71 collection method [4-6]. While effective at diagnosing infection, there is little evidence that RT-72 gPCR cycle threshold (Ct) values from these samples are correlated to viral load, and thereby, 73 virus transmissibility. The amount of viral RNA collected by NP swabs may vary in each sample, 74 and therefore, serves as a poor viral load indicator. Alternatively, the viral load in saliva samples 75 has been well correlated with COVID-19 symptoms and transmissibility [7,8]. Low Ct values are 76 associated with high viral load and increased transmissibility [9]. This correlation is primarily due 77 to viral presence in saliva droplets that facilitate spread when infected individuals are in

proximity. Saliva has been shown to be an accurate diagnostic tool, yielding comparable Ct
values to NP swabs while decreasing both discomfort to patients and risk of transmission to
healthcare workers during collection [10].

81 Methods:

82 Ethical review for this study was obtained by the Institutional Review Board of Clemson 83 University. This is a retrospective study on archived deidentified samples and data. The 84 samples and data sets were striped of patient identifiers prior to any SARS-CoV2 sequencing 85 and data analysis. To evaluate the relative viral load of the variants of concern (VOC) found in 86 upstate South Carolina (Alpha, Gamma, and Delta), we compared the Ct values from saliva 87 samples from the SARS-CoV-2 testing lab at Clemson University, which also provides free 88 testing for the surrounding community [11]. University surveillance testing is mandatory for 89 students and employees on a weekly or bi-weekly schedule regardless of vaccination status 90 [12]. The study population includes all university students and employees, as well as members 91 of the surrounding community that tested positive between January and November 2021. 92 Samples were labeled as "symptomatic" if the patient self-reported symptoms at the time of 93 collection, or "exposed" if they reported recent viral exposure. All other samples were 94 considered "surveillance". Only one positive test was included for each patient; any subsequent 95 tests were excluded from our analysis.

96 SARS-CoV-2 positive saliva samples were identified using the TigerSaliva RT-qPCR 97 testing method, which targets the N gene [11]. Positive controls made from synthetic RNA at 98 200 viral copies/ μ L resulted in a Ct value of approximately 24. It was also determined that a Ct 99 of 33 was equivalent to 1 viral copy/ μ L, and as such any samples with a Ct lower than 33 were 100 considered positive. Samples were run in duplicate, and the average Ct value from both 101 replicates was used for this analysis.

Heat treated saliva samples were commercially sequenced (Premier Medical Sciences,
Greenville, SC; Labcorp, Durham, NC) using the ARTIC protocol. Briefly, RNA was extracted

104 from saliva samples via MagBind Viral RNA Kit (Omega Biotek, Norcross, GA) and recovered 105 SARS-CoV-2 RNA quantity was assessed via Logix Smart COVID-19 assay (Co-Diagnostics, 106 Salt Lake City, UT). Samples with sufficient RNA quantity were sequenced on the Illumina 107 platform using NovaSeg 6000 or NextSeg500/550 flow cell. Sequences were assembled and 108 analyzed using nf-core/viralrecon v.2.2 [13]. Sequence data was uploaded to SC DHEC, 109 GenBank, and GISAID (see Supplementary Data). Some samples had ambiguous regions that 110 prevented database uploads, but all had sufficient information to confidently assign clade by 111 Pangolin and Nexclade. 112 Ct values among VOCs were compared: 20I (Alpha), 21A (Delta), 20G, and 20J 113 (Gamma, V3) [14]. Due to low prevalence in the Upstate SC community, 20H (Beta) samples 114 (n=8) were excluded from analysis. To maintain phylogenetic independence, we only compare 115 Ct values for variants at branch tips within the NextClade phylogeny [15]. 116 **Results and Discussion:** 117 We first determined the clade composition in our community from the sequenced 118 positive samples between January and December 2021 (Fig 1). From January to July, we 119 sequenced all positive samples stored from the lab. Due to the increase in positive samples

during the Delta surge, we sequenced a statistical sampling of positives (approximately 15%) to

121 ensure accurate coverage of our community demographics.







126

127 To compare Ct values, and thereby infectious potential, statistical analyses were 128 performed in an R environment using Kruskal-Wallis test followed by Dunn's test of multiple 129 comparisons (Fig 2). SARS-CoV-2 positive samples showed a significant difference between 130 Delta (median: 22.61, IQR: 16.72-28.51) and all other clades [Alpha: 23.93 (18.36-28.49), 131 Gamma: 24.74 (18.84-30.64), 20G: 25.21 (20.50-29.916)]. When only surveillance samples 132 were considered (Fig 2B), the same trend was observed with Delta (median: 22.56, IQR: 16.67-133 28.45) having a significantly lower median Ct from other clades [Alpha: 23.81 (18.51-29.11), 134 Gamma: 24.69 (18.84-30.54), 20G: 25.75 (21.53-29.98)]. Additionally, both groups showed a 135 significant difference in Ct values between Alpha and 20G.



136

Figure 2: N1 Ct values of common clades in saliva. We analyzed the Ct values from a total 137 138 of 1297 SARS-CoV-2 positive saliva samples, using the N gene target. 2A: Comparison of all 139 samples. Delta (n=787) showed a statistically significant difference in Ct value when compared 140 to 20G (n=159), Alpha (n=258), and Gamma (n=87). 2B: Comparison of surveillance 141 samples. When only surveillance samples were considered, the same trends were observed. 142 showing a significant difference between Delta (n=691) and all other clades (20G: n=95, Alpha: 143 n=181, Gamma: n=86). Both groups also showed a significant difference when comparing Alpha 144 and 20G. 2C. Comparison of symptomatic samples. There were no significant differences in 145 Ct values observed among symptomatic samples for Delta (n=70), Alpha (n=58), Gamma (n=1), and 20G (n = 39). *p.adj<0.05, **p.adj<0.01, ***p.adj<0.001, ****p.adj<0.0001. 146

148 When analyzing only symptomatic samples, we found no statistically significant 149 difference in Ct values amongst the clades (Fig 2C). The benefit of Clemson University's 150 surveillance strategy is that infections are caught early, often before symptoms are present, 151 which decreases the number of symptomatic samples in our population. While there are 152 significant differences in viral loads between the VOC clades and 20G in pre-symptomatic and 153 asymptomatic patients at the time of initial diagnosis, this trend is not necessarily maintained as 154 the disease progresses. This may explain the discordant results in the literature; studies which 155 primarily focused on tests from COVID-19 hospitalized patients did not observe differences in 156 viral loads among the clades [6], whereas studies that included tests from earlier stage 157 diagnoses observed significant differences in viral loads, particularly for Delta [4,5]. 158 Additionally, patients that report symptoms are much more likely to test positive 159 compared to non-symptomatic patients (Fig 3). From January to November 2021, the average 160 positivity rate for symptomatic samples was 12.71% and for surveillance samples was 0.98%. 161 During the surge in cases due to the Alpha variant in March 2021, samples from patients at the 162 community site who reported exposure were much more likely to be positive for SARS-CoV-2 163 when compared to non-exposed (8.8% vs 1.7%). However, after the emergence of Delta, the 164 test positivity rate was 10% in both groups. This is likely due to the overwhelming presence of 165 Delta within our community and the extremely high viral load, likely ensuring that everyone had 166 some level of exposure.



167

Fig 3: Number of tests and positive tests per category, by week. Note that the y-axis is on a log10 scale. Samples are labeled "symptomatic" if the patient reports symptoms at the time of testing, or labeled "exposed" if they report exposure to a positive patient. Surveillance samples represent the rest of the samples collected. The lower case load during week 11 is due to the university's spring break, and weeks 18-29 account for summer break.

173

174 Due to a non-normal data distribution, we performed Kruskal-Wallis test for stochastic

dominance. However, it has been suggested that ANOVA is robust to slight non-normality [16].

176 Reanalyzing the data with Welch's ANOVA, we observed similar results (SFig 1) and

- 177 determined there was approximately an 8-fold difference in viral load between Delta and 20G,
- 178 which is consistent with other studies using NP swabs from initial diagnostic samples [4,5]. Our
- 179 results highlight the significant difference in Ct values between Delta samples and other VOCs.

180 Conclusion:

181	Overall, our study showcases the increased viral load of the Delta variant and provides
182	evidence for its rapid global spread. A major benefit to saliva-based testing is the ease of
183	testing; people are more inclined to test frequently. Specifically, our data show that the Delta
184	VOC has a higher viral load in saliva even in healthy, young individuals who are pre- or
185	asymptomatic. These individuals are not often captured by other studies as they are not likely to
186	seek out testing; however, they are known to contribute to the rapid spread of COVID-19 [17].
187	High infectivity of new variants necessitates accurate surveillance. It is expected that future
188	dominant strains, like the newly emerging Omicron, will have viral loads comparable to or
189	greater than Delta to achieve a competitive advantage.

191 Funding:

- 192 This work is supported by the National Institutes for Health [P20GM121342], Clemson
- 193 University's Vice President for Research, and the South Carolina Governor & Joint Bond
- 194 Review Committee.
- 195

196 Acknowledgements:

- 197 The authors thank Clemson University's administration, medical staff, and the REDDI Lab who
- 198 helped develop and implement SARS-CoV-2 testing. Thank you to Mayor Robert Halfacre and
- 199 Dr. Ted Swann for facilitating Clemson community testing. We thank Dr. Vidhya Narayanan, Dr.
- 200 David Elms, and Russ Nuttall for technical assistance of whole genome sequencing. Thank you
- 201 to Kaitlyn Williams, Rachel Ham, Sujata Srikanth, and Jeremiah Carpenter for sample
- 202 preparation. We thank the REDDI Lab clinical director, Dr. Michael Friez, technical supervisor,
- 203 Dr. Congyue Peng, and clinical supervisors Lauren Cascio and Wael Namouz for maintaining
- high complexity certification standards (CLIA number 42D2193465). We thank Rachel Ham and
- 205 Austin Smothers for their critical reading of this manuscript.
- 206
- 207 Potential Conflicts of Interest: All authors: no reported conflicts of interest or competing
 208 interests.
- 209
- 210 Data accessibility: All relevant data are within the manuscript and its Supporting Information
- 211 files. Data analysis scripts can be found at https://github.com/CUGBF/SARS-CoV-2_Ct-vs-
- 212 Clade.git
- 213

214 **References**:

215		
216	1.	Center for Disease Control. COVID Data Tracker. Available at
217		https://covid.cdc.gov/covid-data-tracker/#datatracker-home. Accessed 2 December
218	_	2021.
219	2.	Cherian, S, Potdar, V, Jadhav, S, <i>et al.</i> SARS-CoV-2 Spike Mutations, L452R, T478K,
220		E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India.
221	2	Microorganisms, 2021; 9(7), 1542.
222	3.	Syed, AW, Tana, TY, Tabata, T, <i>et al.</i> Rapid assessment of SARS-Cov-2 evolved
223 771		variants using virus-like particles. Science (New York, N.Y.), 2021 , eablo104. Auvance
224	4	Tevssou F Delagrèverie H Visseaux B <i>et al</i> The Delta SARS-CoV-2 variant has a
226	т.	higher viral load than the Beta and the historical variants in nasonharvngeal samples
227		from newly diagnosed COVID-19 patients. <i>Journal of Infection</i> . 2021 :83(4), e1–e3.
228	5.	Wang, Y, Chen, R, Hu, F, <i>et al.</i> Transmission, viral kinetics and clinical characteristics of
229		the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. Eclinicalmedicine, 2021;
230		40, 101129.
231	6.	Tani-Sassa, C, Iwasaki, Y, Ichimura, N, et al. Viral loads and profile of the patients
232		infected with SARS-CoV-2 Delta, Alpha, or R.1 variants in Tokyo. Journal of Medical
233		<i>Virology, 2021</i> ; 10.1002/jmv.27479.
234	7.	Huang, N, Pérez, P, Kato, T, <i>et al.</i> SARS-CoV-2 infection of the oral cavity and saliva.
235	~	Nat Med, 2021 ; 27, 892–903.
230 227	ð.	Sarkar B, Sinna RN, Sarkar K. Initial Viral Load of a COVID-19-Infected Case Indicated
237		Predictor of its Transmissibility - An Experience from Quiarat India Indian I Community
239		Med. 2020 : 45(3):278-282.
240	9.	Jefferson, T. Spencer, EA. Brassev, J. Heneghan, C. Viral Cultures for Coronavirus
241	-	Disease 2019 Infectivity Assessment: A Systematic Review. Clinical Infectious Diseases,
242		2021 ; <i>73</i> (11), e3884–e3899.
243	10.	Yokota, I, Hattori, T, Shane, PY, et al. Equivalent SARS-CoV-2 viral loads by PCR
244		between nasopharyngeal swab and saliva in symptomatic patients. Sci Rep, 2021; 11,
245		4500.
246	11.	Ham, R. E., Smothers, A. R., King, K. L., Napalitano, J. M., Swann, T. J., Pekarek, L. G.,
247		Blenner, M. A., Dean, D. Efficient SARS-CoV-2 Quantitative Reverse Transcriptase PCR
248		Saliva Diagnostic Strategy utilizing Open-Source Pipetting Robots. J. Vis. Exp. (Pending
249 250	10	Publication), e63395, In-press (2022). Report L. McMohan, C. Kelbaugh, CA. et al. Surveillance based informative testing for
20U 251	12.	detection and containment of SARS CoV 2 outbrooks on a public university computer on
251		observational and modelling study. The Lancet Child & Adolescent Health 2021: 5(6)
252		428-436
254	13	Patel H Varona S Monzón S <i>et al</i> nf-core/viralrecon: nf-core/viralrecon v2 2 - Tin
255		Turtle (2.2) 2021. Zenodo.
256	14.	https://github.com/CUGBF/SARS-CoV-2 Ct-vs-Clade
257	15.	Aksamentov, I. Roemer, C. Hodcroft, EB. Neher, RA. Nextclade: clade assignment.
258		mutation calling and quality control for viral genomes. <i>Journal of Open Source Software</i> .
259		2021; 6(67), 3773.
260	16.	Blanca, MJ., Alarcón, R, Arnau, J, Bono, R., & Bendayan, R. Non-normal data: Is
261		ANOVA still a valid option?. Psicothema, 2021; 29(4), 552–557.

17. Johansson, MA, Quandelacy, TM, Kada, S, *et al.* SARS-CoV-2 Transmission From
 People Without COVID-19 Symptoms. *JAMA Network Open*, **2021**; *4*(1), e2035057.



267 SFig 1: Analysis of Ct values using Welch's ANOVA test. 1A: Comparison of all samples.

268 We observed a statistically significant difference between Delta and all other clades, including

an 8-fold difference in viral load when compared to 20G. 1B: Comparison of only surveillance

samples. The same difference in median Ct was observed between Delta and all other clades.

Additionally, surveillance samples showed a statistical difference between Alpha and 20G.

272 *p.adj<0.05, **p.adj<0.01, ***p.adj<0.001, ****p.adj<0.0001

273

SFile 1: Accession numbers for sequenced samples uploaded to SCDHEC, GenBank, and
 GISAID.
 276

- 270
- 277
- 278





